I-Tofacitinib citrate 540737-29-9 I-Rheumatoid arthritis I-Anticancer
Inkokhelo:T/T, L/C
Umsuka Womkhiqizo:China
Imbobo yokuthutha:Beijing/Shanghai/Hangzhou
Amandla okukhiqiza:100kg/ngenyanga
I-oda(MOQ):25kg
Isikhathi esiholayo:3 Izinsuku Zokusebenza
Isimo sesitoreji:Igcinwe endaweni epholile, eyomile, izinga lokushisa legumbi.
Impahla yephakheji:isigubhu
Usayizi wephakheji:25kg/isigubhu
Ulwazi lokuphepha:Akuzona izimpahla eziyingozi
Isingeniso
I-Tofacitinib, umuthi osetshenziselwa ukwelapha i-rheumatoid arthritis, i-psoriatic arthritis, kanye ne-ulcerative colitis.
I-Tofacitinib citrate isetshenziselwa ukwelapha abantu abadala abane-arthritis ye-rheumatoid esebenza ngokusesilinganisweni ukuya eqinile abaye baba nempendulo enganele, noma abangayibekezeleli i-methotrexate.
I-Tofacitinib citrate iboniswa ekwelapheni i-arthritis ye-rheumatoid esebenzayo (RA) emaphakathi kuya eqinile kubantu abadala abaphendulile ngendlela efanele, noma abangabekezeleli umuthi owodwa noma ngaphezulu oguqula izifo.
Imininingwane (ekhaya)
| Into | Ukucaciswa |
| Ukubukeka | I-crystalline powder emhlophe noma emhlophe |
| Ukuhlonza | IR, HPLC |
| Amanzi | ≤1.5% |
| Izinto Ezihlobene | I-TOFA 06 ≤0.15% |
| I-Tofacitinib trans isomer ≤0.15% | |
| I-Tofacitinib dehydrogenated ≤0.15% | |
| Ukungcola ngakunye okungaziwa ≤0.10% | |
| Ukungcola Okuphelele: ≤1.0% | |
| Izincibilikisi Ezisele | I-Ethanol ≤5000ppm |
| I-Benzene ≤2ppm | |
| I-Toluene ≤890ppm | |
| I-Chlroroethane ≤1000ppm | |
| N,N-Dimethylformamide ≤800ppm | |
| I-Palladium ≤10ppm | |
| I-Dichloromethane ≤600ppm | |
| Umlotha one-sulphate | ≤0.1% |
| Insimbi Enzima | ≤10ppm |
| I-Chrial HPLC | 3S, 4S tofacitinib ≤0.15% |
| I-Assay (ngokwesisekelo se-anhydrous) 98.0-102.0% |
